European Pharmaceutical News - Latest
ACTICHROME® Heparin (Anti-FXa), Activity Assay REF 832 IVD
ACTICHROME® Heparin (Anti-FXa) is an amidolytic chromogenic assay intended for the quantitative determination of therapeutic heparin in human plasma via the measurement of Factor Xa activity. The inhibitory effect of antithrombin III (ATIII) on Factor IIa (thrombin), Factor Xa, and other coagulation serine proteases in plasma is increased several thousand-fold by heparin. This inhibition accounts for the anticoagulant effect of heparin. Assaying plasma heparin levels by the measurement of their Anti-Factor Xa activity is a necessary tool for monitoring the efficacy of heparin treatment efficacy. Low molecular weight heparin (LMWH) preparations appear to catalyze the reaction between thrombin (FIIa) and AT-III less readily than the reaction between Factor Xa and AT-III. Unfractionated heparin (UFH) catalyzes both reactions equally. ACTICHROME Heparin (Anti-FXa) is a three stage assay. First, plasmas containing heparin incubate with human antithrombin III forming a heparin- ATIII complex. Second, Factor Xa is added which is inhibited by the heparin-ATIII complex. Last, the residual Factor Xa activity hydrolyzes SPECTROZYME® FXa, a Factor Xa specific chromogenic substrate. As both Factor Xa and antithrombin III are in excess, the residual Factor Xa activity measured is inversely proportional to the heparin concentration in the plasma.
Sincerely Pharmaceutical Tech
Client Success Team (CRM),
Please fill the all required fields....!!
Sincerely Packaging Labelling